NCT03260504 2025-12-08
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
University of Washington
Phase 1 Terminated
University of Washington
University of California, San Francisco
Academic and Community Cancer Research United
Eli Lilly and Company